On June 9, the U.S. FDA approved an eight‑week maintenance dosing schedule for Eli Lilly’s EBGLYSS (lebrikizumab‑lbkz), allowing a single injection every eight weeks for patients aged 12 and older with moderate‑to‑severe atopic dermatitis. The change—backed by exposure–response modeling and Phase 3 ADjoin long‑term extension data—makes EBGLYSS the only therapy that can be maintained with as few as six injections per year without prescription topical therapy. In the 32‑week extension, the drug demonstrated durable disease control with no new safety signals; common adverse events included conjunctivitis, injection‑site reactions and herpes zoster.
FDA Approves 8‑Week Maintenance Dosing for Eli Lilly’s EBGLYSS, Allowing As Few As Six Injections Per Year
FDA Approves New Eight-Week Maintenance Dosing Regimen for Eli Lilly’s (LLY) EBGLYSS
On June 9, the U.S. Food and Drug Administration approved an updated maintenance dosing regimen for Eli Lilly’s EBGLYSS (lebrikizumab‑lbkz), permitting adults and adolescents aged 12 and older with moderate‑to‑severe atopic dermatitis to receive a single injection once every eight weeks.
Under the revised label, EBGLYSS becomes the only available therapy that can be maintained with as few as six injections per year without the requirement for concomitant prescription topical treatments, potentially simplifying long‑term disease management for many patients.
Evidence Behind the Change
The dosing update was supported by longitudinal exposure–response modeling and data from the Phase 3 ADjoin long‑term extension study. Regulators reviewed outcomes from the 32‑week extension, which demonstrated sustained disease control and informed authorization of the extended dosing interval.
Safety And Tolerability
In the 32‑week extension of ADjoin, EBGLYSS showed durable control of symptoms with no new safety signals identified. The trial reported no patient discontinuations attributed to adverse events. The most commonly observed adverse events were consistent with the established safety profile and included conjunctivitis, injection‑site reactions and herpes zoster.
Clinical And Patient Implications
Eli Lilly’s management said the eight‑week maintenance option offers greater flexibility for patients and may reduce the burden of frequent injections and daily symptom management. For clinicians, the updated regimen expands practical treatment options for moderate‑to‑severe atopic dermatitis and may support adherence for patients seeking fewer clinic visits or self‑administration events.
About The Company: Eli Lilly and Company (NYSE: LLY) is a global healthcare firm that develops pharmaceutical products in areas including cardiometabolic health, oncology and immunology. The FDA’s approval broadens EBGLYSS’s utility as a long‑term treatment option for eligible patients with atopic dermatitis.
Help us improve.
